Cefdinir for Oral Suspension — Class II drug recall D-247-2013
Terminated recall by Teva Pharmaceuticals USA, Inc., reported 2013-04-17, distributed nationwide. Defective Container: This recall is being carried out due to the potential for improperly sealed bottles.
| Recall number | D-247-2013 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Inc., Sellersville, PA, United States |
| Recall initiated | 2013-02-26 |
| Classified | 2013-04-10 |
| Reported by FDA | 2013-04-17 |
| Terminated | 2014-01-15 |
| Distributed | Nationwide (US) |
| Quantity | 62,187 bottles |
| Reason classes | packaging |
| NDC | 00093-4136, 00093-4136-64, 00093-4136-73, 00093-4137, 00093-4137-64, 00093-4137-73 |
| Lot numbers | 03/14, 12/13, 30304144A, 30304253A, 30304477A |
Product
Cefdinir for Oral Suspension, 125 mg/5 mL, packaged in a) 60 mL bottle (NDC 0093-4136-64); b) 100 mL bottle (NDC 0093-4136-73), Rx only, Teva Pharmaceuticals USA, Sellersville, PA 18960.
Reason for recall
Defective Container: This recall is being carried out due to the potential for improperly sealed bottles.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-247-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.